AU780284B2 - Immunosurpressive effects of pteridine derivatives - Google Patents

Immunosurpressive effects of pteridine derivatives Download PDF

Info

Publication number
AU780284B2
AU780284B2 AU24418/00A AU2441800A AU780284B2 AU 780284 B2 AU780284 B2 AU 780284B2 AU 24418/00 A AU24418/00 A AU 24418/00A AU 2441800 A AU2441800 A AU 2441800A AU 780284 B2 AU780284 B2 AU 780284B2
Authority
AU
Australia
Prior art keywords
dimethyl
dimethyllumazine
pharmaceutical composition
lumazine
pteridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU24418/00A
Other languages
English (en)
Other versions
AU2441800A (en
Inventor
Piet Andre Maurits Maria Herdewijn
Wolfgang Eugen Pfleiderer
Mark Jozef Albert Waer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4-AZA BIOSCIENCE NV
Original Assignee
4 AZA Bioscience NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4 AZA Bioscience NV filed Critical 4 AZA Bioscience NV
Publication of AU2441800A publication Critical patent/AU2441800A/en
Assigned to 4-AZA BIOSCIENCE NV reassignment 4-AZA BIOSCIENCE NV Alteration of Name(s) of Applicant(s) under S113 Assignors: K.U. LEUVEN RESEARCH & DEVELOPMENT
Application granted granted Critical
Publication of AU780284B2 publication Critical patent/AU780284B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU24418/00A 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives Ceased AU780284B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11828299P 1999-02-02 1999-02-02
US11823599P 1999-02-02 1999-02-02
US11829599P 1999-02-02 1999-02-02
US60/118282 1999-02-02
US60/118295 1999-02-02
US60/118235 1999-02-02
PCT/EP2000/000938 WO2000045800A2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Publications (2)

Publication Number Publication Date
AU2441800A AU2441800A (en) 2000-08-25
AU780284B2 true AU780284B2 (en) 2005-03-10

Family

ID=27382128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24418/00A Ceased AU780284B2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Country Status (5)

Country Link
EP (1) EP1187615A2 (ja)
JP (1) JP2002536320A (ja)
AU (1) AU780284B2 (ja)
CA (1) CA2361561A1 (ja)
WO (1) WO2000045800A2 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
MXPA02007868A (es) 2000-02-16 2003-02-10 Neurogen Corp Arilpirazinas sustituidas.
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
AU2003258307A1 (en) 2002-08-20 2004-03-11 Neurogen Corp 5-substituted-2-arylpyrazines as modulators of crf receptors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2005056547A2 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
PL2297106T3 (pl) 2008-05-27 2015-01-30 Galderma Sa Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
WO2016118823A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CA3182389A1 (en) * 2020-07-03 2022-01-06 Bin Lin Anti-inflammatory compositions, methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1998052948A1 (en) * 1997-05-19 1998-11-26 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
WO1994014065A1 (en) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
WO1997039358A1 (en) * 1996-04-15 1997-10-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services In vitro prognostic test for progressors and non-progressors after hiv infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1998052948A1 (en) * 1997-05-19 1998-11-26 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MED CHEM VOL 39 NO.1 PP 2-9 *

Also Published As

Publication number Publication date
JP2002536320A (ja) 2002-10-29
EP1187615A2 (en) 2002-03-20
AU2441800A (en) 2000-08-25
CA2361561A1 (en) 2000-08-10
WO2000045800A2 (en) 2000-08-10
WO2000045800A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
AU780284B2 (en) Immunosurpressive effects of pteridine derivatives
EP0956855B1 (en) Immunosuppressive effects of 8 substituted xanthine derivatives
EP3515916B1 (en) Shp2 phosphatase inhibitors and methods of use thereof
US6946465B2 (en) Immunosuppressive effects of pteridine derivatives
JP4267697B2 (ja) 免疫抑制性化合物および方法
CN101084227B (zh) 雷帕霉素类似物及其治疗神经紊乱、增殖性和炎性疾病的用途
EP1144412B1 (en) Immunosuppressive effects of pteridine derivatives
DE60025385T2 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
EP1077715B1 (en) Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process
US20030191307A1 (en) 2,4-Diaminopyrimidine compounds useful as immunosuppressants
UA111739C2 (uk) Імідазопіридазини як інгібітори аkt-кінази
US6046328A (en) Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative
JP2021518344A (ja) Ａｔｒキナーゼの複素環式阻害剤
JP3464230B2 (ja) ピリダジンジオン化合物、該化合物を含有する神経障害を治療するための医薬組成物、動物の神経障害を治療する方法、及び該化合物の製造方法
JP4339679B2 (ja) Ｐｄｅ５阻害剤としてのカルボリン誘導体
CA2584261A1 (en) Pharmaceutical composition
US7253176B1 (en) Immunosuppressive effects of 8-substituted xanthine derivatives
JP2014501234A (ja) 置換ピリミド［１，２−ｂ］インダゾールおよびＰＩ３Ｋ／ＡＫＴ経路のモジュレーターとしてのそれらの使用
SU1056901A3 (ru) Способ получени сесквитерпеновых производных или их солей
AU757489B2 (en) Method for inhibiting cytokine production by cells
KR20080083194A (ko) 이미다조[1,2-α]피리딘-3-일-아세트 산 하이드라자이드,이들의 제조 방법 및 이들의 용도
JP2003520768A (ja) ＴＮＦα阻害剤として有用なチアゾロピリミジン
CA2519026A1 (en) Therapeutic and/or preventive agent for chronic skin disease
JPS627167B2 (ja)
US3906097A (en) Method of producing a depressant effect using 5-cyclopropyl-1,2,4-oxadiazol-3-yl diazines